Arcolane

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arcolane

Quick Facts

Property Description
Active Ingredient Ketoconazole
Pharmacological Class Azole Antifungal / Antimycotic
Primary Forms Shampoo, Topical Cream, Solution
Route of Administration Topical (External Skin and Scalp)
Origin Synthetic (Imidazole Derivative)

What Type of Medicine is Arcolane (Ketoconazole)?

Arcolane is a pharmaceutical preparation defined by its core active substance, Ketoconazole, which is chemically classified as a synthetic imidazole derivative. This compound is classified by authoritative bodies as an azole antifungal agent, belonging to the broader category of antimycotic medications. The robust classification of Ketoconazole as a targeted antifungal is widely supported by pharmacological studies, confirming its efficacy against pathogenic overgrowths.

Arcolane's Composition and Physical Form

The medicine is a single-ingredient formulation designed exclusively for topical use, intended for direct application to the affected external surface, often targeting the scalp. Arcolane is most commonly presented as a specialized shampoo, a form recognized for its ease of application across larger surface areas, though a topical cream or solution is also available. The formulation relies on a hydrophilic or aqueous vehicle, which ensures the action of Ketoconazole is localized to the treated area. This topical route is a key feature, confining the antifungal effect to the site of application.

Primary Therapeutic Purpose

The fundamental purpose of this potent antimycotic agent is to gain effective control over the growth and proliferation of fungal and yeast populations residing on the skin or scalp. The core mechanism is achieved by interfering with the synthesis of ergosterol, a crucial structural component required for fungal cell survival. Ketoconazole's ability to interrupt this essential process is clinically recognized, offering a proven, specific strategy to reduce the overall microbial load, thereby helping to restore the natural microbial balance of the affected surface.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Arcolane?

Possible Side Effects and Safety Information

Officially Documented Adverse Reactions

The safety profile of topical ketoconazole is defined primarily by localized reactions at the site of application, consistent with the medicine's minimal systemic absorption. Regulatory classifications categorize possible adverse effects based on their frequency, as documented in clinical trials and post-marketing surveillance.

Frequency Category Representative Adverse Reactions (SmPC Terminology)
Common (1-10 in 100 users) Skin burning sensation, Application site pruritus, Application site erythema.
Uncommon (1-10 in 1,000 users) Hypersensitivity, Contact dermatitis, Bullous eruption, Application site irritation, Increased lacrimation.
Frequency Not Known Anaphylaxis, Angioedema, Urticaria, Alopecia (hair loss), Abnormal hair texture, Hair colour changes.

Serious Reactions and Safety Constraints

Serious adverse reactions, identified during post-marketing experience, include reports of anaphylaxis and severe hypersensitivity reactions. The medicine is contraindicated in individuals with known hypersensitivity to the active ingredient or any component of the formulation.

Local effects, such as a burning sensation or redness resulting from excessive topical application, are explicitly documented as resolving upon discontinuation of treatment. Furthermore, the product is not for ophthalmic use.

Population and Contextual Safety Notes

Safety and effectiveness have not been established in children. For pregnant and nursing women, regulatory guidance states that use should only occur if the potential benefit justifies the potential risk, given the lack of adequate studies. A specific safety note advises that when transitioning from prolonged topical corticosteroid use, the steroid should be gradually withdrawn to mitigate a potential rebound effect.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for topical Ketoconazole formulations, such as Arcolane, specifies that systemic toxicity is not anticipated following intended use due to minimal absorption through the skin. The primary risk scenario addressed in labeling is accidental oral ingestion of the shampoo or cream preparation.

When Immediate Medical Help Is Required

In the event of accidental ingestion, you must seek immediate medical attention and contact emergency services. Management is strictly defined by regulatory authorities as supportive and symptomatic treatment.

Management Instruction Official Regulatory Statement
Primary Concern Potential for systemic effects following large accidental ingestion.
Antidote No specific antidote is known for this overdose scenario.
Prohibited Procedures Emesis (vomiting) and gastric lavage are contraindicated and must be avoided to eliminate the risk of pulmonary aspiration.
Required Action Management should focus on supportive and symptomatic measures under clinical observation.

The regulatory guidance strictly prohibits the induction of vomiting or gastric lavage due to the documented danger of aspiration, which constitutes the most severe acute risk associated with accidental ingestion of the topical product. This emphasizes that professional medical care is required immediately to ensure correct supportive management is initiated.

Therapeutic Uses of Arcolane

What Arcolane Treats: Main Uses and Benefits

Topical ketoconazole is generally applied in clinical settings that involve acute or disruptive symptom patterns stemming from fungal and yeast activity on the skin. The medication is commonly used across therapeutic domains where short-term symptom management is appropriate for these types of skin issues.

The primary therapeutic focus of this antifungal may be part of symptomatic management for conditions such as tinea pedis, tinea cruris, tinea corporis, seborrheic dermatitis, and pityriasis versicolor. Arcolane helps address symptom clusters that may become intense or disruptive, such as flaking, burning, redness, and persistent pruritus (itching). This use may provide supportive relief that helps ease the overall symptom burden.

“This approach may help support the patient during difficult episodes by easing distress and contributing to maintaining a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Inflammatory Skin Discomfort

The medication may play a role in managing conditions characterized by periods of heightened symptoms, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations, particularly those related to chronic scaling and irritating skin conditions.

Regulatory References

  1. National Library of Medicine DailyMed label for Ketoconazole Cream, 2%

Eligibility and Restrictions for Use

Who Can and Cannot Use Arcolane?

Eligibility for Arcolane (Topical Ketoconazole) is determined strictly by official regulatory labeling, defining populations that are contraindicated or require conditional use.

Contraindicated Populations

  • Use is contraindicated for any person with a known hypersensitivity to ketoconazole or to any of the specific excipient ingredients in the formulation.
  • The medicine is strictly contraindicated for ophthalmic use (application to the eyes).
  • Formulations containing sodium sulfite anhydrous are contraindicated for individuals with a known sulfite sensitivity.

Age-Related Eligibility

  • Use is generally established for adults and adolescents 12 years of age and older.
  • Safety and effectiveness have not been established for children younger than 12 years for the cream and shampoo formulations.

Conditional and Restricted Use

  • Pregnancy: Use is conditional (e.g., Pregnancy Category C), meaning the potential benefit must justify the potential risk.
  • Lactation: Caution must be exercised; it is not known if the medicine is excreted into breast milk following topical application.
  • Organ Impairment: No specific eligibility restriction is documented for hepatic or renal impairment due to the minimal systemic absorption of the topical form.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the documented interaction patterns for Arcolane (topical Ketoconazole), strictly based on official government regulatory sources.

Negligible Systemic Drug-Drug Interaction Risk

Official regulatory documentation confirms that the risk of systemic drug-drug interactions is considered negligible for topical ketoconazole. Formal drug interaction studies have typically not been performed with the topical gel or shampoo formulations. The active substance is generally not detected in plasma following chronic or repeated external use, which indicates that the potential for pharmacokinetic interactions (such as those mediated by CYP enzymes) is extremely low. Consequently, the severe contraindications associated with oral ketoconazole, such as co-administration with CYP3A4-sensitive medicines like simvastatin or triazolam, do not apply to the topical product.


Administration Timing Requirements and Cautions

Regulatory labels specify constraints related to administration sequencing and formulation ingredients:

  • Topical Corticosteroids: A timing rule is mandated for patients transitioning from long-term topical corticosteroid therapy. The official prescribing information requires that the steroid be gradually withdrawn over a period of two to three weeks while initiating ketoconazole to prevent a potential skin rebound effect.
  • Excipient Caution: Some forms of ketoconazole cream may contain the excipient sodium sulfite. Regulatory documents carry a caution that this non-active ingredient can cause allergic-type reactions, including asthmatic episodes, in susceptible individuals, particularly those with a history of asthma.

Mechanism of Action

The mechanism of action for the active ingredient, Ketoconazole, is an interaction that affects the cellular structure of susceptible fungal organisms, operating at the molecular level to disrupt essential biosynthetic processes.

Molecular Inhibition of Fungal Sterol Synthesis

Ketoconazole acts as a specific inhibitor of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51A1). By physically binding to this critical enzyme, the molecule halts the metabolic pathway responsible for creating ergosterol, the primary sterol necessary for fungal cell structure.

Structural Failure and Antifungal Consequence

The enzyme blockade leads to a dual physiological effect: the critical depletion of ergosterol and the accumulation of toxic, methylated sterol intermediates within the cell membrane. This combination fundamentally compromises the membrane's integrity and fluidity, causing cell contents to leak and preventing the fungus from multiplying or growing, resulting in the physiological consequence of inhibiting fungal proliferation.

Mechanistic Constraint via Target Resistance

The mechanism is biologically constrained by the potential for fungal resistance, which arises when genetic mutations occur in the target enzyme itself. These changes can weaken the drug's inhibitory binding affinity, allowing the enzyme to continue synthesizing enough ergosterol to override the intended mechanism.

Dosage and Administration Information

How to Use Arcolane

Arcolane, containing ketoconazole, is approved solely for topical administration, meaning it is applied directly to the affected external skin or scalp. The medicine is commercially available as a 2% cream and a 2% shampoo/suspension. Its use is standardized by the specific formulation and the condition being addressed, following schedules detailed in regulatory documents.


Official Usage Protocols

Usage Aspect Standardized Protocol Duration & Frequency Pattern
Cream (2%) Applied to cover the affected area and the immediate surrounding skin. Typically once daily for tinea infections, or twice daily for seborrheic dermatitis. Courses range from 2 to 6 weeks.
Shampoo (2%) Applied to damp hair/skin, lathered, and must be left in place for 3 to 5 minutes before rinsing. Twice weekly for 2–4 weeks (treatment of seborrheic dermatitis). Used less frequently, such as once every 1–2 weeks, for prophylaxis.

Administration Requirements

The 2% formulations are indicated for use in adults and adolescents; safety in children younger than 12 years has not been universally established across regulatory labels. Procedurally, if the shampoo contacts the eyes, the area should be rinsed with water. For patients transitioning from long-term topical corticosteroid therapy, regulatory instructions recommend a gradual withdrawal over 2 to 3 weeks while beginning ketoconazole application to manage the potential for rebound effects. This approach defines the standardized, non-advisory regimen for Arcolane use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Arcolane (Topical Ketoconazole)

This section provides a factual overview of the types of research and studies that have been conducted on topical ketoconazole. It describes the structure of the evidence and highlights areas that remain under review, without offering any clinical advice or making statements about how the medicine will work for an individual.


Evidence for Use in Superficial Fungal Infections (Dermatophytoses)

The evidence base for conditions like Tinea Corporis, Tinea Cruris, and Tinea Pedis was evaluated primarily through Randomized Controlled Trials (RCTs). Researchers examined outcomes related to physical discomfort and fungal presence. Studies monitored both clinical signs, such as the change in erythema (redness), scaling, and pruritus (itching), and specific microbial endpoints, such as measurement of the potential clearance of fungus (mycological cure). Findings describe patterns observed in these short-term studies, and some trials described different measurement patterns when topical ketoconazole was studied alongside other topical agents.

What remains uncertain: Follow-up durations were limited in much of the core research, meaning there is limited information for long-term outcomes or how often symptoms may return after the treatment period ends. Additionally, comparative evidence may be mixed.


Evidence for Use in Seborrheic Dermatitis

Topical ketoconazole was evaluated in managing seborrheic dermatitis, which is characterized by fluctuating or episodic manifestations, through Systematic Reviews and Meta-Analyses. Studies monitored patient experiences using structured scales to quantify outcomes linked to inflammatory or irritative states, such as the severity of scaling and pruritus. They also examined mycological clearance, which relates to the monitored status of Malassezia yeast populations on the skin's surface. Studies report how symptoms changed in the observed populations relative to the non-medicated vehicle.

What remains uncertain: The evidence quality varies across studies due to heterogeneity (variability) in how different studies defined the optimal treatment schedule. Subgroup findings are uncertain for many groups not included in the primary trials.

Key Studies & References

  1. Label: KETOCONAZOLE- ketoconazole cream, 2% cream - DailyMed (Official Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Arcolane (FAQ)


Q: How quickly can a person expect to see any changes after starting Arcolane?

A: Regulatory documents indicate that clinical improvement may be observed following the start of treatment. However, to ensure the infection is fully addressed and to reduce the possibility of it recurring, official usage protocols recommend completing the entire treatment course, which typically ranges from two to six weeks.


Q: Can women who are pregnant or breastfeeding use Arcolane?

A: According to the official product information, use during pregnancy is conditional because there are no adequate and well-controlled studies in pregnant women. Regarding breastfeeding, official information indicates caution should be exercised because it is unknown if the medicine is excreted into human milk following topical application.


Q: Can children or adolescents use Arcolane?

A: Regulatory labels generally establish use for adolescents aged 12 years and older. Official information states that safety and effectiveness for the cream and shampoo forms have not been established in children younger than 12 years of age.


Q: Does Arcolane have a black box warning from the FDA?

A: The topical formulation of the medicine does not carry an FDA Black Box Warning. The specific significant warnings, such as those related to liver toxicity, are associated with the oral form of the active ingredient and are described as not applicable to the topical product.


Q: Do other chronic health conditions affect eligibility for Arcolane use?

A: No specific restriction is documented for chronic systemic conditions like hepatic (liver) or renal (kidney) impairment due to minimal systemic absorption. However, official documents carry a caution regarding the excipient, sodium sulfite anhydrous, in some formulations, as this non-active ingredient may cause allergic-type reactions in susceptible individuals, particularly those with a history of asthma.


Q: What if I'm taking multiple other medications—is Arcolane still appropriate?

A: Regulatory documentation confirms the risk of systemic drug-drug interactions is considered very low for the topical formulation. This is because the active substance is generally not detected in the bloodstream following external application.


Q: Is Arcolane the same as other medicines for the same condition, or is it different?

A: Arcolane contains the active ingredient ketoconazole, which is classified as an azole antifungal agent. This places it within the antimycotic class of medicines used to control fungal and yeast growth on the skin and scalp.


Q: Can Arcolane be taken with common pain relievers like ibuprofen?

A: The potential for systemic interaction with common oral pain relievers, such as ibuprofen, is described as very low. This is based on regulatory information that indicates the topical medicine is generally not detected in the bloodstream after external application.


Q: Are there any known foods or drinks that should be avoided when taking Arcolane?

A: Because the systemic absorption of the topical medicine is minimal, there are generally no restrictions or required changes to a person's diet or consumption of foods and drinks described in the official product information.


Q: Does Arcolane cause drowsiness or affect the ability to drive?

A: Side effect profiles documented in clinical trials for the topical medicine primarily focus on localized skin reactions at the application site. Systemic effects such as drowsiness are not commonly reported with its use.


Q: Is Arcolane available as a generic medicine?

A: Yes, the active ingredient, ketoconazole, is widely available in lower-cost generic forms, in addition to the brand-name versions.


Q: Why is it sometimes recommended to keep taking Arcolane even after symptoms improve?

A: Official usage protocols for certain infections recommend completing the full course of treatment as prescribed. This protocol is described as being in place to reduce the possibility of the infection recurring.


Q: Are there different strengths or forms (like tablets vs. liquid) of Arcolane?

A: The medicine is generally available in various topical forms intended for external use only. These include a 2% cream, a 2% shampoo/suspension, and topical foam, with the concentration standardized at 2% for prescription use.


Q: Does Arcolane interact with herbal supplements like St. John's Wort?

A: Since systemic absorption of the topical medicine into the bloodstream is minimal, the potential for interactions with oral herbal supplements is considered very low.


Q: Is Arcolane considered a 'controlled substance'?

A: No, the medicine is not classified as a controlled substance under regulatory scheduling in the United States.


Q: What if Arcolane doesn't seem to be working after the first week?

A: Official treatment courses range from two to six weeks depending on the condition. If no clinical improvement is observed after the entire recommended treatment period is completed, regulatory instructions suggest the initial diagnosis should be checked again.


Q: Can Arcolane affect blood sugar levels?

A: Blood sugar effects are not listed among the documented side effects for the topical medicine. Systemic effects like this are generally associated with medicines that are highly absorbed into the bloodstream.


Q: How does Arcolane compare to over-the-counter options for the same purpose?

A: Studies have examined the medicine alongside other topical agents, and research findings described different measurement patterns and outcomes observed during these comparisons.


Q: What is the typical length of time a person might use Arcolane?

A: Official usage protocols define an initial duration of use for a treatment course that ranges from two to six weeks, depending on the condition. For certain conditions, a maintenance regimen may be described in regulatory documents for use as infrequently as once every one to two weeks.


Q: Are there any known risks of taking Arcolane with alcohol?

A: Regulatory information indicates that, due to minimal systemic absorption, there is generally a very low systemic risk when combining its use with alcohol.


Q: Does taking Arcolane with food help reduce stomach upset?

A: Since the medicine is for external application to the skin or scalp only, instructions related to taking a medicine with food do not apply. Topical use is not documented to cause stomach upset.


Q: Are there any known severe or rare side effects associated with Arcolane?

A: Yes, officially documented rare or serious reactions identified during post-marketing experience include reports of anaphylaxis and severe hypersensitivity reactions.


Q: Can Arcolane interact with birth control pills?

A: Due to the minimal systemic absorption of the topical medicine, the potential for interaction with oral hormonal contraceptives, such as birth control pills, is considered negligible.


Q: How does the research evidence for Arcolane compare to other established medicines?

A: Studies have examined the medicine alongside other topical agents, and research findings described different measurement patterns and outcomes observed during these comparisons.


Q: Is Arcolane available only by prescription?

A: The availability of the medicine varies by the formulation and concentration. Some formulations are available only by prescription, while lower strengths for conditions like dandruff may be available over-the-counter.


Q: Can Arcolane affect sleep patterns?

A: Changes in sleep patterns are not listed among the common or uncommon side effects documented for the topical formulation in regulatory documents.


Q: Does Arcolane have a potential for dependence or withdrawal symptoms?

A: Regulatory documentation does not report or suggest a potential for dependence or withdrawal symptoms specifically related to stopping the use of topical Arcolane itself.


Q: Are there any known genetic factors that affect how Arcolane works?

A: The medicine's mechanism of action is biologically constrained by the potential for fungal resistance. This resistance can arise when genetic mutations occur in the target fungal enzyme responsible for sterol synthesis, weakening the drug's inhibitory effect.


Q: Does Arcolane interact with vitamin supplements?

A: The minimal systemic absorption of the topical medicine indicates the potential for interactions with oral vitamin supplements is very low.


Q: Does Arcolane require any special monitoring like blood tests?

A: Due to the minimal systemic absorption of the topical formulation, routine medical monitoring, such as blood tests, is generally not documented as being required during its use.

How should Arcolane be stored and disposed of?

The storage and disposal of Arcolane (ketoconazole foam, 2%) must strictly adhere to the conditions documented in regulatory labeling to maintain stability and ensure safety.

Official Storage Requirements

Arcolane must be stored at controlled room temperature (20 to 25 C / 68 to 77 F). Due to its pressurized, flammable nature, the container must not be exposed to heat, direct sunlight, or temperatures above 49 C (120 F). Users must not puncture or incinerate the container and must avoid fire or flame during and immediately after application. The medication must always be kept out of the reach of children.

Disposal Instructions

Disposal should follow official guidelines. If a drug take-back program is unavailable, unused Arcolane may be disposed of by mixing it with an undesirable substance (such as coffee grounds) and placing the mixture in a sealed container before discarding it in the trash. Identifying information on the prescription label must be completely scratched out prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arcolane found in:

A-Z Index: